Response to Comments: Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

This article responds to public comments about coverage of skin substitute grafts/cellular and tissue‑based products for diabetic foot ulcers and venous leg ulcers but is not a standalone coverage decision and does not itself add or exclude services. Key points: all submitted comments were reviewed and addressed (some topics combined or cross‑referenced) during the open comment period, and actual coverage remains governed by the existing contractor policies and requirements.